Eli Lilly Q1 2026: Revenue Surges 56% as GLP-1 Boom Deepens
Eli Lilly beat Q1 2026 estimates with $19.8B revenue (+56%), EPS of $8.26 (+170%), driven by Mounjaro, Zepbound, and newly launched oral pill Foundayo.
Eli Lilly beat Q1 2026 estimates with $19.8B revenue (+56%), EPS of $8.26 (+170%), driven by Mounjaro, Zepbound, and newly launched oral pill Foundayo.
Learn what the five options Greeks actually mean — delta, gamma, theta, vega, and rho — with worked examples, a data table, and charts that show how each measure changes in real market conditions.
Lincoln International filed an S-1 with the SEC to list on NYSE under ticker LCLN. With $783.8M in 2025 revenue and Goldman Sachs and Morgan Stanley as underwriters, here’s what it means for capital markets.
NXP Semiconductors surged 26% — its best day since listing in 2010 — as Q1 earnings beat estimates and Q2 guidance of up to $3.55B signaled a chip recovery led by auto and AI.
Learn how options work — what calls and puts are, how premiums are priced, and the difference between intrinsic and extrinsic value. Includes payoff diagrams.
Meta, Alphabet, Amazon and Microsoft will spend ~$700B on AI in 2026 — debt-funding is flooding the investment-grade bond market with record supply.
Meta, Alphabet, Amazon, and Microsoft posted Q1 2026 earnings beats this week—combined revenues hit $430 billion as AI investments begin delivering measurable results across the board.
The P/E ratio is Wall Street’s most-quoted valuation metric. Here’s what it measures, how to calculate it, and the five ways it can mislead you.
Bill Ackman’s Pershing Square raises $5B in a dual NYSE IPO but shares sink ~18% on debut as retail demand misses the original $25B target.
Bloom Energy (BE) surges 23% after Q1 2026 revenue jumps 130% to $751M on AI data center demand; full-year revenue guidance raised to $3.4B–$3.8B.